Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally. Effective management ...

Forbes contributors publish independent expert analyses and insights. Zak Doffman writes about security, surveillance and privacy. Despite what you might have read, iPhone remains ahead of Android ...

Apple’s delayed iPhone update is now just hours away. iOS 26.1 is a real game-changer, further widening the security and privacy gap to Android as both mobile ecosystems fight the scourge of spyware ...

Not happy with your LG TV's factory settings? Try these tweaks to get the most out of your movies and shows. Aryan writes to simplify tech complexities for readers. He integrates his engineering ...

Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...

GSK’s respiratory drug lineup spans a newly approved product for chronic obstructive pulmonary disease as well as therapeutic candidates in various stages of clinical development for treating this ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

“This new COPD diagnostic schema, which includes chest imaging, respiratory symptoms and spirometry, identified additional individuals at risk of poor respiratory outcomes,” said Bhatt, a professor in ...

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken a hit after the anti-ST2 monoclonal antibody failed to reduce flare-ups in ...